RP
RPID.US Rapid Micro Biosystems Inc
- Market cap
- USD 37.0M
- P/E
- -
- P/B
- 1.85x
- ROE
- -582.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RPID.US undervalued?
Graham numberThe Graham number of Rapid Micro Biosystems Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rapid Micro Biosystems Inc fundamental analysis
No fundamental analysis for Rapid Micro Biosystems Inc yet.
Rapid Micro Biosystems Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rapid Micro Biosystems Inc
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and …
Full company profileRapid Micro Biosystems Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rapid Micro Biosystems Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2010 | 2011 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 16.1M | 11.0M | 16.5M | 16.1M | 23.2M | 17.1M | 22.5M | 28.1M | 33.6M | 34.1M |
| Gross Profit | 59.0K | - | -234K | -8.07M | -7.74M | -8.54M | -5.49M | -109K | 7.61M | 5.31M |
| Operating Income | - | - | -18.6M | -30.5M | -47.2M | -63.2M | -56.6M | -49.9M | -47.4M | -49.1M |
| EBITDA | - | - | -16.9M | -32.0M | -69.3M | -60.4M | -49.3M | -43.5M | -42.7M | -46.8M |
| Net Income | - | - | -21.2M | -37.1M | -73.5M | -60.8M | -52.5M | -46.9M | -47.1M | -51.3M |
| EPS | - | - | -0.53 | -0.96 | -1.77 | -1.43 | -1.22 | -1.08 | -1.05 | -1.05 |
| Balance Sheet | ||||||||||
| Total Assets | 2.32M | 1.66M | 31.7M | 70.0M | 241M | 191M | 143M | 98.2M | 74.9M | 47.6M |
| Total Liabilities | 5.02M | 6.84M | 32.4M | 45.2M | 20.2M | 26.5M | 25.5M | 22.8M | 41.6M | 38.8M |
| Shareholders' Equity | -2.70M | -5.17M | -725K | 24.8M | 221M | 164M | 118M | 75.4M | 33.2M | 8.81M |
| Cash & Short-term Investments | 156K | 1.00K | 12.5M | 45.1M | 193M | 109M | 92.1M | 50.7M | 38.3M | 6.72M |
| Total Debt | - | - | 17.8M | 24.8M | 400K | 7.97M | 7.35M | 6.17M | 23.9M | 23.2M |
| Cash Flow | ||||||||||
| Operating Cash Flow | - | - | -21.1M | -31.0M | -55.0M | -58.5M | -45.1M | -44.2M | -31.1M | -55.5M |
| Capital Expenditure | 6.00K | 3.00K | 1.70M | 690K | 3.22M | 6.74M | 1.85M | 1.37M | 850K | 1.23M |
| Free Cash Flow | - | - | -22.8M | -31.7M | -58.2M | -65.3M | -46.9M | -45.5M | -31.9M | -55.9M |
| Ratios | ||||||||||
| ROE | - | - | - | -149.4% | -33.3% | -37.0% | -44.5% | -62.2% | -141.9% | -582.2% |
| ROA | - | - | -66.8% | -53.0% | -30.5% | -31.9% | -36.6% | -47.8% | -63.0% | -107.8% |
| Net Profit Margin | - | - | -128.2% | -230.6% | -316.5% | -354.9% | -233.0% | -167.2% | -140.3% | -150.4% |
| Debt to Equity | - | - | - | 1.00x | 0.00x | 0.05x | 0.06x | 0.08x | 0.72x | 2.64x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rapid Micro Biosystems Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 186K | 0.00 | - |
| 2022 | USD 566K | 0.01 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2011 | - | - | - |
| 2010 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Oct 29, 2010.
Who owns Rapid Micro Biosystems Inc
- Insiders 10.11%
- Institutions 43.94%
- Public & others 45.96%
- Shares outstanding 45.7M
- Free float 23.9M
Top funds holding RPID.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 751K | 1.50% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 113K | 0.23% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 111K | 0.22% | -0.38% | Sep 2026 |
| Fidelity Total Market Index | 31.5K | 0.06% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 29.5K | 0.06% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 28.7K | 0.06% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 14.4K | 0.03% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 11.6K | 0.02% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 11.6K | 0.02% | 0.00% | Oct 2026 |
| Dimensional Global Core Equity USD Acc | 8.65K | 0.02% | -0.30% | Sep 2026 |
| 1290 VT Micro Cap K | 7.52K | 0.02% | 0.00% | Sep 2026 |
| Dimensional World Equity GBP Acc | 4.13K | 0.01% | -0.22% | Sep 2026 |
| Dimensional Gl Cor Eq LC ESG Sc USD A | 3.09K | 0.01% | -0.39% | Sep 2026 |
| Dimensional US Core Equity USD Acc | 3.01K | 0.01% | 0.00% | Sep 2026 |
| Dimensional International Core Eq Acc | 2.98K | 0.01% | 0.00% | Sep 2026 |
| Dimensional Global Small Coms USD Acc | 2.09K | 0.00% | 0.00% | Sep 2026 |
| BlackRock Global Equity Mkt Netrl Instl | 468.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding RPID.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8.43M | 16.82% | 0.00% | Jun 2026 |
| Armistice Capital, LLC | 3.33M | 6.63% | 0.00% | Jun 2026 |
| ABG-WTT Global Life Science Capital Partners GP Ltd | 1.85M | 3.68% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 982K | 1.96% | -0.05% | Jun 2026 |
| Evernest Financial Advisors LLC | 506K | 1.01% | +16.99% | Jun 2026 |
| Advent International LP | 380K | 0.76% | -31.24% | Jun 2026 |
| Essex Investment Management Company, LLC | 363K | 0.72% | -58.97% | Jun 2026 |
| Renaissance Technologies Corp | 240K | 0.48% | +13.15% | Sep 2026 |
| Millennium Management LLC | 237K | 0.47% | -16.48% | Jun 2026 |
| Geode Capital Management, LLC | 228K | 0.45% | -7.74% | Jun 2026 |
| BlackRock Inc | 190K | 0.38% | +20.73% | Jun 2026 |
| Legato Capital Management LLC | 120K | 0.24% | -56.52% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 110K | 0.22% | +0.70% | Jun 2026 |
| State Street Corp | 93.9K | 0.19% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 79.7K | 0.16% | +30.55% | Jun 2026 |
| SEI Investments Co | 66.9K | 0.13% | -76.52% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 63.5K | 0.13% | -39.05% | Sep 2026 |
| Acadian Asset Management LLC | 60.0K | 0.12% | 0.00% | Sep 2026 |
| Northern Trust Corp | 42.1K | 0.08% | -12.79% | Jun 2026 |
| Algert Global LLC | 38.3K | 0.08% | +65.25% | Jun 2026 |
Rapid Micro Biosystems Inc company profile
- Company name
- Rapid Micro Biosystems Inc
- Ticker
- RPID.US
- Exchange
- USA Stocks
- Listed since
- Jul 15, 2021
- Sector
- Healthcare
- Industry
- Wireless Telecommunication Services
- Employees
- 171
- Fiscal year end
- December
- Address
- 25 Hartwell Avenue, Lexington, MA, United States, 02421
- Phone
- 978 349 3200
- Website
- rapidmicrobio.com
About Rapid Micro Biosystems Inc
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Rapid Micro Biosystems Inc management
7- Mr. Robert G. Spignesi Jr.CEO, President, COO & Director · born 1970
- Mr. Sean M. Wirtjes CPAChief Financial Officer · born 1969
- Mr. Michael Beaulieu C.F.A.Vice President of Investor Relations & Corporate Communications
- Mr. James XuSenior VP of Legal & Secretary
- Ms. Katherine AtkinsonSenior VP of Global Sales & Marketing
- Ms. Julie JarvieSenior VP of Human Resources
- Mr. Chris RobinsonSenior Vice President of Operations